Beranda › Kanker Payudara › North Carolina
Uji klinis Kanker Payudara di North Carolina
91 studi untuk Kanker Payudara mencari peserta di lokasi di North Carolina.
Kota di North Carolina
- Durham64 studi
- Charlotte22 studi
- Winston-Salem14 studi
- Concord5 studi
- Shelby5 studi
- Greensboro5 studi
- Gastonia4 studi
- High Point4 studi
- Greenville4 studi
- Asheville3 studi
- Raleigh3 studi
Teks studi resmi (Bahasa Inggris)
The Vanguard Study: Testing a New Way to Screen for Cancer
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill
- Durham VA Medical Center, Durham
Menerima pesertaSukarelawan sehat diterima
Usia 45 hingga 75 · Semua jenis kelamin · Diperbarui 5 Okt 2026 · NCT06995898Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis
- Comprehensive Cancer Center at Wake Forest University (CCCWFU), Winston-Salem
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 5 Okt 2026 · NCT02422641A Study of PHST001 in Advanced Solid Tumors
- Duke Cancer Institute, Durham
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 5 Okt 2026 · NCT06840886The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- Duke University, Durham
Menerima pesertaFase 1/2
Usia 12 ke atas · Semua jenis kelamin · Diperbarui 2 Okt 2026 · NCT04585750Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
- Duke Cancer Network, Durham
- Cone Health Cancer Center, Greensboro
Menerima pesertaFase 3
Usia 18 hingga 100 · Semua jenis kelamin · Diperbarui 2 Okt 2026 · NCT05827081Distance-Based Exercise to Preserve Function and Prevent Disability
- Novant Health Cancer Institute - Kernersville, Kernersville
- Novant Health Cancer Institute - Mount Airy, Mount Airy
- Novant Health Forsyth Medical Center, Winston-Salem
Menerima peserta
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 2 Okt 2026 · NCT07059884Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- AdventHealth Infusion Center Asheville, Asheville
- Southeastern Medical Oncology Center-Clinton, Clinton
- AdventHealth Infusion Center Haywood, Clyde
- dan 6 lainnya
Menerima pesertaStudi observasionalSukarelawan sehat diterima
Usia 40 hingga 75 · Semua jenis kelamin · Diperbarui 2 Okt 2026 · NCT05334069A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer
- Levine Cancer, Charlotte
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 1 Okt 2026 · NCT07102381Low Dose Aspirin for the Prevention of Postpartum Related Breast Cancer
- University of North Carolina, Chapel Hill
Menerima pesertaFase 2Sukarelawan sehat diterima
Usia 18 hingga 45 · Wanita · Diperbarui 1 Okt 2026 · NCT05557877A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer
- UNC Hospitals, University of North Carolina at Chapel Hill, Chapel Hill
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 1 Okt 2026 · NCT06369285Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors
- Carolina BioOncology Institute, LLC - Cancer Therapy and Research Center, Huntersville
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 29 Sep 2026 · NCT07360314Radiation Therapy and Thymus Function in Young Women With Breast Cancer
- Duke Cancer Center, Durham
Menerima pesertaStudi observasional
Usia 18 hingga 50 · Wanita · Diperbarui 29 Sep 2026 · NCT07725172BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors
- Duke Cancer Center, Durham
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 28 Sep 2026 · NCT06120283Evaluation of the Acceptability, Appropriateness, and Feasibility/Usability of a Metastatic Breast-cancer Specific Prognostic Calculator Among Clinicians
- University of North Carolina, Chapel Hill
Menerima pesertaStudi observasionalSukarelawan sehat diterima
Semua usia · Semua jenis kelamin · Diperbarui 28 Sep 2026 · NCT05440929A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
- Novant Health Cancer Institute ( Site 0019), Charlotte
- Novant Health Oncology Specialists ( Site 0074), Winston-Salem
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 28 Sep 2026 · NCT07060807A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
- Levine Cancer Institute ( Site 0014), Charlotte
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT06312176The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study
- Levine Cancer Institute, Albemarle
- Levine Cancer Institute, Charlotte
- Levine Cancer Institute, Charlotte
- dan 11 lainnya
Menerima pesertaFase 3
Usia 60 ke atas · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT06377852ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer
- Duke Cancer Institute, Durham
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT07007559Multicenter Trial for Eliminating Breast Cancer Surgery or Radiotherapy in Exceptional Responders to Neoadjuvant Systemic Therapy
- Carolinas Medical Center/Levine Cancer Institute, Charlotte
Menerima peserta
Usia 30 ke atas · Wanita · Diperbarui 25 Sep 2026 · NCT02945579Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer
- Atrium Levine Cancer Institute, Charlotte
Menerima peserta
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 23 Sep 2026 · NCT07214532Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
- Clinical Trial Site, Charlotte
- Clinical Trial Site, Durham
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 23 Sep 2026 · NCT07085767A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
- Duke University Medical Center, Durham
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 22 Sep 2026 · NCT07213791A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
- Messino Cancer Centers, Asheville
- WakeMed Cancer Care - Waverly Hematology & Medical Oncology, Cary
- University of North Carolina Medical Center, Chapel Hill
- dan 1 lainnya
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 22 Sep 2026 · NCT07174336A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer
- University of North Carolina Medical Center, Chapel Hill
Menerima pesertaFase 2
Usia 18 ke atas · Wanita · Diperbarui 22 Sep 2026 · NCT07287098A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer
- Atrium Health, Charlotte
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 21 Sep 2026 · NCT05894239Identifying Patterns in the Breath of Individuals With Breast Cancer
- Duke University Medical Cente, Durham
Menerima pesertaStudi observasionalSukarelawan sehat diterima
Usia 40 hingga 74 · Wanita · Diperbarui 18 Sep 2026 · NCT06512350Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 18 Sep 2026 · NCT07340541ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
- Oncology Specialists of Charlotte Pa, Charlotte
- Carolina Oncology Specialists, Charlotte
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 17 Sep 2026 · NCT07173751Pharmacologic Therapies to Mitigate Radiation- Associated Heart Disease
- Lineberger Comprehensive Cancer Center at University of North Carolina, Chapel Hill, Chapel Hill
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 17 Sep 2026 · NCT07685938Utility of a Mobile Application for Young Women With Breast Cancer
- Atrium Health Levine Cancer, Charlotte
Menerima peserta
Usia 18 hingga 45 · Wanita · Diperbarui 15 Sep 2026 · NCT07009093A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
- Duke Cancer Institute, Durham
- Cape Fear Valley Medical Center, Fayetteville
- Cone Health Cancer Center at Wesley Long, Greensboro
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 15 Sep 2026 · NCT06492616Integrating Biological, Clinical, and Behavioral Factors to Improve Breast Cancer Outcomes - Carolina Breast Cancer Study
- University of North Carolina at Chapel Hill, Chapel Hill
Menerima pesertaStudi observasional
Usia 20 hingga 74 · Wanita · Diperbarui 14 Sep 2026 · NCT07214610A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
- Research Site, Charlotte
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 11 Sep 2026 · NCT05123482A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
- Duke Cancer Institute, Durham
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 10 Sep 2026 · NCT03424005A Phase 1/1b Study of IAM1363 in HER2 Cancers
- Duke Cancer Institute, Durham
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 9 Sep 2026 · NCT06253871A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer
- Levine Cancer Institute, Charlotte
- Novant Health Cancer Institute, Charlotte
- Novant Health Oncology Specialists, Winston-Salem
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 8 Sep 2026 · NCT07100106Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration
- Duke Cancer Institute, Durham
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 4 Sep 2026 · NCT05315700A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
- Novant Health Cancer Institute, Charlotte
- Duke Cancer Institute, Durham
- Novant Health Cancer Institute, Winston-Salem
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 3 Sep 2026 · NCT06790693Toci +/- SOC Chemo for Metastatic Triple Negative and ER-positive, HER2-negative Breast Cancers
- Duke University, Durham
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 3 Sep 2026 · NCT05846789Ultra Hypo-fractionated Adjuvant Whole Breast Radiation Therapy With Simultaneous Integrated Boost for Early-Stage Breast Cancer (H-ASSIST)
- University of North Carolina, Chapel Hill
Menerima pesertaFase 2
Usia 50 ke atas · Wanita · Diperbarui 3 Sep 2026 · NCT06902311Dari ClinicalTrials.gov, data diambil 6 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.